Cite
HARVARD Citation
Daver, N. et al. (2022). Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of clinical oncology. 40 (35), pp. 4048-4059. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Daver, N. et al. (2022). Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of clinical oncology. 40 (35), pp. 4048-4059. [Online].